The United States Food and Drug Administration (FDA) on Saturday approved the use of casirivimab and imdevimab for the treatment of mild to moderate coronavirus disease 2019 (Covid-19) in adults and pediatric patients over age 12.
The two drugs were used to treat President Donald Trump after he contracted Covid-19 last October.
The FDA said it has issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate Covid-19 in adults and pediatric patients over age 12.
“The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic,” Dr. Patrizia Cavazzoni, M.D., acting director of the FDA’s Center for Drug Evaluation and Research, said in a press statement. SOVEREIGNPH